A phase 4 single-arm open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.
Brief description of study
The purpose of the study is to evaluate the safety, efficacy, and tolerability of combined treatment: pembrolizumab and carboplatin and paclitaxel for patients with recurrent/ metastatic head and neck squamous cell carcinoma. The combined treatment is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.
Clinical Study Identifier: s20-01498
ClinicalTrials.gov Identifier: NCT04489888
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
